arimoclomol: Clinical Trials

11 trials of arimoclomol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated, 1 available, 1 withdrawn. 7 Phase 2, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 1, Withdrawn 1
Phase 36Completed 4, Terminated 2

Follow arimoclomol: new trials by email Literature Review of arimoclomol trials Research Report on arimoclomol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Arimoclomol - Amyotrophic Lateral Sclerosis
Phase 3TerminatedZevraDenmark1202019-09-192023-08-24
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Arimoclomol - Inclusion Body Myositis
Phase 3TerminatedZevraDenmark1212019-05-202023-09-15
Arimoclomol in Amyotropic Lateral Sclerosis
Arimoclomol, Placebo - Amyotrophic Lateral Sclerosis
Phase 3CompletedZevraDenmark2452018-07-312023-08-24
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Arimoclomol, Placebo oral capsule - Gaucher Disease, Type 1, Gaucher Disease, Type 3
Phase 2TerminatedZevraDenmark392018-06-062023-01-11
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Arimoclomol, Placebo - Inclusion Body Myositis
Phase 2CompletedZevraDenmark1522017-08-162023-05-10
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
arimoclomol, Placebo - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedZevraDenmark502016-06-142024-11-29
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
Arimoclomol, Placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedUniversity of Miami382009-01-012019-01-11
Arimoclomol in Sporadic Inclusion Body Myositis
Arimoclomol, Placebo - Inclusion Body Myositis
Phase 2 / Phase 3CompletedRichard Barohn, MD242008-09-012017-01-19
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
arimoclomol - Amyotrophic Lateral Sclerosis (ALS)
Phase 2CompletedCytRx802005-10-012012-02-09
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Placebo, Arimoclomol - Amyotrophic Lateral Sclerosis
Phase 2WithdrawnCytRx2012-02-09
Early Access Program With Arimoclomol in US Patients With NPC
Arimoclomol - Niemann-Pick Disease, Type C
AvailableZevraDenmark2024-08-16

Conditions studied

Amyotrophic Lateral Sclerosis (5)  ·  Myositis, Inclusion Body (3)  ·  Niemann-Pick Disease, Type C (2)  ·  Gaucher Disease (1)  ·  Lysosomal Storage Diseases (1)  ·  Motor Neuron Disease (1)  ·  Myositis (1)  ·  Neuromuscular Diseases (1)

Sponsors

ZevraDenmark (7)  ·  CytRx (2)  ·  Richard Barohn, MD (1)  ·  University of Miami (1)

Countries

United States (10)  ·  United Kingdom (6)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Poland (3)  ·  Spain (3)  ·  Belgium (2)  ·  Netherlands (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Denmark (1)  ·  India (1)

Top investigators

Merit Cudkowicz, MD, MSc (2)  ·  Michael Benatar, MD PhD (2)  ·  Aabha Nagral, MD (1)  ·  Jeremy Shefner, MD (1)  ·  Jeremy Shefner, MD, PhD (1)  ·  Karl-Eugen Mengel (1)  ·  Mazen Dimachkie, MD (1)  ·  Mazen M Dimachkie (1)  ·  Merit Cudkowicz, MD (1)  ·  Michael Benatar, MBChB, DPhil (1)  ·  Michael Hanna (1)  ·  Michael Hanna, MD (1)

Results publications

PMID 29367439, PMID 34418116, PMID 37739573, PMID 38782015, PMID 38960586